Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

dianhydro-3,4-diacetylgalactitol

Known as: diacetyl-diepoxydulcitol, diacetyldianhydrodulcitol, diacetyldianhydrogalactitol 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Dianhydrogalactitol
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol…
Methods and compositions suitable for the treatment of malignancies in subjects with a germline deletion polymorphism that blocks… Expand
2011
2011
Inhibitory effect of diacetyldianhydrogalactitol on transplanted hepatocarcinoma 22 growth and angiogenesis in mice
Objective: To explore the anti-tumor and anti-angiogenesis effect of diacetyldianhydrogalactitol(DADAG) on hepatocarcinoma H22 in… Expand
2009
2009
Inhibition of Diacetyldianhydrogalactitol on Ornithine Decarboxylase Activity and Its Possible Mechanisms
OBJECTIVE We explored the effects of diacetyldianhydrogalac- titol (DADAG) on ornithine decarboxylase (ODC) activity and the… Expand
2009
2009
Anticancer activity and mechanisms of diacetyldianhydrogalactitol on hepatoma QGY-7703 cells
Diacetyldianhydrogalactitol (DADAG) is a member of the hexitols which shows a significant anticancer effect. Despite the fact… Expand
2006
2006
Inhibitory effect of diacetyldianhydrogalactitol on leukemic L1210 cells
Objective To observe the effect of diacetyldianhydrogalactitol(DADAG) on mouse L1210 leukemia and investigate the mechanism of… Expand
2004
2004
Relation between dose, plasma concentration and toxicity in a phase I trial using high dose intermittent administration of an alkylating agent, diacetyldianhydrogalactitol (DADAG)
SummaryDiacetyldianhydrogalactitol (DADAG), a new alkylating sugar alcohol derivative, was administered as single, 30-min… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
2004
2004
Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG)
SummaryDiacetyldianhydrogalactitol (DADAG), a new alkylating hexitol derivative, was given in 30-min infusions for 5 consecutive… Expand
  • figure 1
  • figure 3
  • table 2
  • table 3
  • table 4
2004
2004
The role of comparative pharmacokinetics in the planning of human dose escalation: the experience with diacetyldianhydrogalactitol
SummaryThe pharmacokinetics of diacetyldianhydrogalactitol (DADAG) was compared in mice, rats, and humans. The ratios of human… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2002
2002
[Apoptosis induced by diacetyldianhydrogalactitol and its mechanism in HL-60 leukemia cells].
AIM To investigate the apoptosis induced by diacetyldianhydrogalactitol (DADAG) and its mechanism in human HL-60 leukemia cells… Expand
2002
2002
Experimental study of antitumor effect of diacetyldianhydrogalactitol on brain leukemia and its mechanism
Objective To study the inhibitory effects of diacetyldianhydrogalactitol (DADAG) on brain leukemia and its mechanism. Method To… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE